UK regulators say that people who have a “significant history’’ of allergic reactions shouldn’t receive the new Pfizer-BioNTech vaccine while they investigate two adverse reactions that occurred on the first day of the country’s mass vaccination program.
Professor Stephen Powis, national medical director for the National Health Service in England, says health authorities were acting on a recommendation from the Medical and Healthcare Products Regulatory Agency.
“As is common with new vaccines the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination after two people with a history of significant allergic reactions responded adversely yesterday,’’ Powis says in a statement. “Both are recovering well.”
The comments come as Dr. June Raine, head of the MHRA, told a Parliamentary committee that regulators had received reports of two allergic reactions from the vaccine.
Undated file photo shows a volunteer receiving the coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. (John Cairns/University of Oxford via AP, File)
“We know from the very extensive clinical trials that this wasn’t a feature,” she says. “But If we need to strengthen our advice, now that we have had this experience with the vulnerable populations, the groups who have been selected as a priority, we get that advice to the field immediately.”
Raine’s comments come as part of a general discussion of how her agency will continue to monitor people who receive the vaccine authorized for emergency use last week.
— AP
Watch Docu Nation Season 2: Resilience
when you join the ToI Community
Support The Times of Israel's independent journalism and receive access to our documentary series, Docu Nation: Resilience, premiering December 12.
In this season of Docu Nation, you can stream eight outstanding Israeli documentaries with English subtitles and then join a live online discussion with the filmmakers. The selected films show how resilience, hope, and growth can emerge from crisis.
When you watch Docu Nation, you’re also supporting Israeli creators at a time when it’s increasingly difficult for them to share their work globally.
To learn more about Docu Nation: Resilience, click here.
Support ToI and get Docu Nation
Support ToI and get Docu Nation
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel eleven years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this